Insmed (INSM) Total Liabilities (2010 - 2026)
Insmed (INSM) recorded quarterly Total Liabilities of $1.4 billion in Q1 2026, down 10.13% quarter-over-quarter from $1.5 billion in Q4 2025, and down 19.52% on a YoY basis from $1.7 billion in Q1 2025.
Insmed (INSM) Total Liabilities (2010 - 2026) Analysis & Trends
Insmed's Total Liabilities history runs 17 years deep, the most recent figure standing at $1.4 billion for Q1 2026.
- In Q1 2026, Total Liabilities fell 19.52% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $1.4 billion (down 19.52% YoY), while the FY2025 annual figure was $1.5 billion, down 12.32% from the prior year.
- Total Liabilities was $1.4 billion for Q1 2026 at Insmed, down from $1.5 billion in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $1.8 billion in Q2 2024 to a low of $1.0 billion in Q2 2022.
- Historically, Total Liabilities has averaged $1.5 billion across 5 years, with a median of $1.6 billion in 2022.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities soared 110.58% in 2022, then tumbled 30.55% in 2025.
- A 5-year view of Total Liabilities shows it stood at $1.6 billion in 2022, then climbed by 5.95% to $1.7 billion in 2023, then grew by 4.7% to $1.7 billion in 2024, then slipped by 12.32% to $1.5 billion in 2025, then decreased by 10.13% to $1.4 billion in 2026.
- The last three Total Liabilities figures came in at $1.4 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1.74 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 15.48 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 731.60 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 19.51 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 10.44 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 943,068.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 7.12 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 137.56 Mn |
| 10 | Insmed | 19.79 Bn | 18.57 Bn | 258.54 Mn | 1.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.37 Bn |
| Dec 31, 2025 | 1.53 Bn |
| Sep 30, 2025 | 1.42 Bn |
| Jun 30, 2025 | 1.23 Bn |
| Mar 31, 2025 | 1.70 Bn |
| Dec 31, 2024 | 1.74 Bn |
| Sep 30, 2024 | 1.57 Bn |
| Jun 30, 2024 | 1.77 Bn |
| Mar 31, 2024 | 1.62 Bn |
| Dec 31, 2023 | 1.66 Bn |
| Sep 30, 2023 | 1.61 Bn |
| Jun 30, 2023 | 1.59 Bn |
| Mar 31, 2023 | 1.56 Bn |
| Dec 31, 2022 | 1.57 Bn |
| Sep 30, 2022 | 1.02 Bn |
| Jun 30, 2022 | 1.01 Bn |
| Mar 31, 2022 | 1.03 Bn |
| Dec 31, 2021 | 833.04 Mn |
| Sep 30, 2021 | 806.93 Mn |
| Jun 30, 2021 | 698.73 Mn |